Mechanisms of immunotherapy resistance in small cell lung cancer

Abstract

Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a poor prognosis. Although the addition of immunotherapy to chemotherapy has modestly improved outcomes, most patients rapidly develop resistance. Resistance to immunotherapy can be broadly categorized into primary resistance and acquired resistance, as proposed by the Society for Immunotherapy of Cancer (SITC) consensus definition. Primary resistance occurs in the setting of failure to respond to immune checkpoint inhibitors (ICIs), while acquired resistance develops after initial response. The mechanisms of acquired and primary resistance to ICI are not well understood in SCLC, denoting an area of critical unmet need.

Both intrinsic and extrinsic mechanisms play significant roles in immunotherapy resistance. Intrinsic mechanisms include defects in antigen presentation, mutations in key genes, reduced tumor immunogenicity, and epigenetic alterations. Extrinsic mechanisms involve the tumor microenvironment (TME), which is a complex interplay of both tumor- and immunosuppressive immune cells, vasculature, and microbiome.

An understanding of these resistance mechanisms is crucial for developing novel therapeutic strategies to advance effective immunotherapy in patients with SCLC, a critical area of unmet need.

Keywords

Immunotherapy resistance / small cell lung cancer / biomarker / primary resistance / acquired resistance

References

[1] Ferlay J, Ervik M, Lam F, et al. Global cancer observatory factsheet: lung. Global cancer observatory: cancer today. 2024. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today. [Last accessed on 25 Dec 2024].

[2] Molina JR,Cassivi SD,Adjei AA.Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.Mayo Clin Proc2008;83:584-94 PMCID:PMC2718421

[3] Cohen S,Banerjee M.Temporal trends in small cell lung cancer: analysis of the U.S. surveillance, epidemiology and end results (SEER) database.JCO2023;41:e20641-e20641

[4] Micke P,Metz T.Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer-what limits limited disease?.Lung Cancer2002;37:271-6

[5] Tseng JS,Chen KC.Association of smoking with patient characteristics and outcomes in small cell lung carcinoma, 2011-2018.JAMA Netw Open2022;5:e224830 PMCID:PMC8968543

[6] Früh M,Popat S,Peters S.ESMO Guidelines Working GroupSmall-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol2013;24:vi99-105

[7] Steffens CC,Hutzschenreuter U.TLK-Group (Tumour Registry Lung Cancer)Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.Lung Cancer2019;130:216-25

[8] Blackhall F,Livartowski A.Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study.BMJ Open2023;13:e052556 PMCID:PMC9906168

[9] Fujimoto D,Tamiya M.Outcomes of chemoimmunotherapy among patients with extensive-stage small cell lung cancer according to potential clinical trial eligibility.JAMA Netw Open2023;6:e230698 PMCID:PMC9958526

[10] Peters S,Dafni U.ETOP/IFCT 4-12 STIMULI CollaboratorsConsolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.Ann Oncol2022;33:67-79

[11] Ardizzoni A,Dombernowsky P.Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.J Clin Oncol1997;15:2090-6

[12] Ahn MJ,Felip E.DeLLphi-301 InvestigatorsTarlatamab for patients with previously treated small-cell lung cancer.N Engl J Med2023;389:2063-75

[13] Paz-Ares L,Reinmuth N.Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.ESMO Open2022;7:100408 PMCID:PMC9161394

[14] Horn L,Szczęsna A.IMpower133 Study GroupFirst-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.N Engl J Med2018;379:2220-9

[15] Liu SV,Mansfield AS.Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133).J Clin Oncol2021;39:619-30 PMCID:PMC8078320

[16] Paz-Ares L,Chen Y.CASPIAN investigatorsDurvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.Lancet2019;394:1929-39

[17] Cheng Y,Wu L.ASTRUM-005 Study GroupEffect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial.JAMA2022;328:1223-32

[18] Reck M,Szczesna A.Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer.J Clin Oncol2016;34:3740-8

[19] Antonia SJ,Bendell J.Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.Lancet Oncol2016;17:883-95

[20] Ott PA,Hiret S.Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study.J Clin Oncol2017;35:3823-9

[21] Ready NE,Hellmann MD.Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort.J Thorac Oncol2020;15:426-35

[22] Chung HC,Lopez-Martin J.Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies.J Thorac Oncol2020;15:618-27

[23] Vaddepally RK,Pandey R,Chandra AB.Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence.Cancers2020;12:738 PMCID:PMC7140028

[24] Owonikoko TK,Govindan R.Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451.J Clin Oncol2021;39:1349-59

[25] Spigel DR,Ciuleanu TE.Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331^☆.Ann Oncol2021;32:631-41

[26] Rudin CM,Navarro A.KEYNOTE-604 InvestigatorsPembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study.J Clin Oncol2020;38:2369-79 PMCID:PMC7474472

[27] Cheng Y,Cho BC.ADRIATIC InvestigatorsDurvalumab after chemoradiotherapy in limited-stage small-cell lung cancer.N Engl J Med2024;391:1313-27

[28] Wang J,Yao W.CAPSTONE-1 Study GroupAdebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2022;23:739-47

[29] Cheng Y,Zhang W.Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.Nat Med2024;30:2967-76

[30] Thomas A,Szabo E.Characteristics and outcomes of small cell lung cancer detected by CT screening.Chest2018;154:1284-90 PMCID:PMC6335258

[31] Rizvi N,Cao ZA.Society for immunotherapy of cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.J Immunother Cancer2023;11:e005920 PMCID:PMC10016262

[32] Kluger HM,Ascierto ML.Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance Taskforce.J Immunother Cancer2020;8:e000398 PMCID:PMC7174063

[33] National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) for small cell lung cancer V.2.2025. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462. [Last accessed on 25 Dec 2024]

[34] Faivre-Finn C,Ashcroft L.CONVERT Study TeamConcurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.Lancet Oncol2017;18:1116-25

[35] Sutherland KD,Brouns I,Song JY.Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.Cancer Cell2011;19:754-64

[36] Rekhtman N,Febres-Aldana CA.Chromothripsis-mediated small cell lung carcinoma.Cancer Discov2024;

[37] Dowlati A,Chan T.Immune checkpoint blockade outcome in small-cell lung cancer and its relationship with retinoblastoma mutation status and function.JCO Precis Oncol2022;6:e2200257 PMCID:PMC9489185

[38] Poirier JT,Connis N.DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.Oncogene2015;34:5869-78 PMCID:PMC4564363

[39] Dowlati A,McColl K.Clinical correlation of extensive-stage small-cell lung cancer genomics.Ann Oncol2016;27:642-7 PMCID:PMC4803453

[40] Gay CM,Park EM.Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.Cancer Cell2021;39:346-360.e7 PMCID:PMC8143037

[41] Rudin CM,Byers LA.Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.Nat Rev Cancer2019;19:289-97 PMCID:PMC6538259

[42] Baine MK,Lai WV.SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization.J Thorac Oncol2020;15:1823-35

[43] Nabet BY,Lee MC.Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.Cancer Cell2024;42:429-443.e4

[44] Dora D,Yu H.Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.Mol Oncol2020;14:1947-65 PMCID:PMC7463307

[45] Mahadevan NR,Wolff JO.Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity.Cancer Discov2021;11:1952-69

[46] Chan JM,Gao VR.Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer.Cancer Cell2021;39:1479-1496.e18 PMCID:PMC8628860

[47] George J,Jang SJ.Comprehensive genomic profiles of small cell lung cancer.Nature2015;524:47-53

[48] Wang F,Zhou Q.The resistance mechanisms of lung cancer immunotherapy.Front Oncol2020;10:568059 PMCID:PMC7606919

[49] O'Donnell JS,Scolyer RA,Smyth MJ.Resistance to PD1/PDL1 checkpoint inhibition.Cancer Treat Rev2017;52:71-81

[50] Ricciuti B,Alessi JV.Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels.JAMA Oncol2022;8:1160-8

[51] McGranahan N,Rosenthal R.Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.Science2016;351:1463-9

[52] Yu H,Badzio A.PD-L1 Expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung cancer.J Thorac Oncol2017;12:110-20 PMCID:PMC5353355

[53] Thomas A,Trindade C.Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study.J Thorac Oncol2019;14:1447-57

[54] Dietel M,Salanova R.Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter EXPRESS study.Lung Cancer2019;134:174-9

[55] Aggarwal C,Felip E.Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024.Ann Oncol2016;27:vi363

[56] Chen HZ,Paruchuri A.Genomic and transcriptomic characterization of relapsed SCLC through rapid research autopsy.JTO Clin Res Rep2021;2:100164 PMCID:PMC8474405

[57] Carvajal-Hausdorf D,Velcheti V.Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC).J Immunother Cancer2019;7:65 PMCID:PMC6408760

[58] Sivakumar S,Montesion M.Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation.Cancer Discov2023;13:1572-91 PMCID:PMC10326603

[59] Hellmann MD,Awad MM.Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer.Cancer Cell2018;33:853-861.e4 PMCID:PMC6750707

[60] Gettinger S,Hastings K.Impaired HLA class i antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer.Cancer Discov2017;7:1420-35 PMCID:PMC5718941

[61] Dhatchinamoorthy K,Rock KL.Cancer immune evasion through loss of MHC class i antigen presentation.Front Immunol2021;12:636568 PMCID:PMC7986854

[62] Ritz U.The Transporter associated with antigen processing (TAP): structural integrity, expression, function, and its clinical relevance.Mol Med2001;7:149-58 PMCID:PMC1950029

[63] Garbi N,Diehl AD.Impaired immune responses and altered peptide repertoire in tapasin-deficient mice.Nat Immunol2000;1:234-8

[64] Liu X,Bai Y,Simister NE.Activation of the JAK/STAT-1 signaling pathway by IFN-gamma can down-regulate functional expression of the MHC class I-related neonatal Fc receptor for IgG.J Immunol2008;181:449-63

[65] Shin DS,Escuin-Ordinas H.Primary resistance to PD-1 blockade mediated by JAK1/2 mutations.Cancer Discov2017;7:188-201 PMCID:PMC5296316

[66] Zaretsky JM,Shin DS.Mutations associated with acquired resistance to PD-1 blockade in melanoma.N Engl J Med2016;375:819-29 PMCID:PMC5007206

[67] Funa K,Minna JD.Paucity of beta 2-microglobulin expression on small cell lung cancer, bronchial carcinoids and certain other neuroendocrine tumors.Lab Invest1986;55:186-93

[68] Doyle A,Funa K.Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.J Exp Med1985;161:1135-51 PMCID:PMC2187608

[69] He Y,Rivard CJ.MHC class II expression in lung cancer.Lung Cancer2017;112:75-80

[70] Mangalhara KC,Johnson MA.Manipulating mitochondrial electron flow enhances tumor immunogenicity.Science2023;381:1316-23 PMCID:PMC11034774

[71] Peressini M,Massuti B.Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.Clin Cancer Res2024;30:3036-49

[72] Taura M,Koyama K.Rb/E2F1 regulates the innate immune receptor toll-like receptor 3 in epithelial cells.Mol Cell Biol2012;32:1581-90 PMCID:PMC3318576

[73] Markey MP,Bosco EE.Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function.Oncogene2007;26:6307-18

[74] Lenahan SM,Deming P.STK11 loss leads to YAP1-mediated transcriptional activation in human KRAS-driven lung adenocarcinoma cell lines.Cancer Gene Ther2024;31:1-8

[75] Zavitsanou AM,Hao Y.KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.Cell Rep2023;42:113295 PMCID:PMC10755970

[76] Papillon-Cavanagh S,Dobrin R,Walsh AM.STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort.ESMO Open2020;5:e000706 PMCID:PMC7199918

[77] Fabrizio FP,Gorgoglione G.Effects of KEAP1 silencing on NRF2 and NOTCH Pathways in SCLC cell lines.Cancers2024;16:1885 PMCID:PMC11120002

[78] Umemura S,Makinoshima H.Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.J Thorac Oncol2014;9:1324-31 PMCID:PMC4154841

[79] Chen J,Jakasekara WSN.MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.J Exp Clin Cancer Res2023;42:100 PMCID:PMC10131464

[80] Markovits E,Baruch EN.MYC induces immunotherapy and IFNγ resistance through downregulation of JAK2.Cancer Immunol Res2023;11:909-24

[81] Li L,Yu M.Advances in immune checkpoint inhibitors therapy for small cell lung cancer.Cancer Med2023;12:11097-106 PMCID:PMC10242320

[82] Burr ML,Chan KL.An evolutionarily conserved function of rolycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer.Cancer Cell2019;36:385-401.e8

[83] Augert A,Ibrahim AH.Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.Sci Signal2019;12 PMCID:PMC6530478

[84] Nguyen EM,Chan JM.Targeting lysine-specific demethylase 1 rescues major histocompatibility complex class I antigen oresentation and overcomes programmed death-ligand 1 blockade resistance in SCLC.J Thorac Oncol2022;17:1014-31

[85] Rudin CM,Lai WV.Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation.J Thorac Oncol2023;18:1222-32 PMCID:PMC10524620

[86] Wang W,McLaren F.Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3⁺ cells in tumour infiltrate.Int J Cancer2012;131:E928-37

[87] Matsumoto A,Mori K,Ohmori Y.Differential anti-tumor effects of IFN-inducible chemokines CXCL9, CXCL10, and CXCL11 on a mouse squamous cell carcinoma cell line.Med Sci2023;11:31 PMCID:PMC10204432

[88] Dangaj D,Grimm AJ.Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors.Cancer Cell2019;35:885-900.e10 PMCID:PMC6961655

[89] Peng D,Nagarsheth N.Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.Nature2015;527:249-53 PMCID:PMC4779053

[90] Tumeh PC,Yearley JH.PD-1 blockade induces responses by inhibiting adaptive immune resistance.Nature2014;515:568-71 PMCID:PMC4246418

[91] Mirlekar B.Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: its implications in cancer immunotherapy.SAGE Open Med2022;10:20503121211069012 PMCID:PMC8793114

[92] Zhou J,Lei A.Neutrophils and PMN-MDSC: their biological role and interaction with stromal cells.Semin Immunol2018;35:19-28 PMCID:PMC5866202

[93] Umansky V,Gebhardt C.The role of myeloid-derived suppressor cells (MDSC) in cancer progression.Vaccines2016;4:36 PMCID:PMC5192356

[94] Wu Y,Niu M,Wu K.Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.Mol Cancer2022;21:184 PMCID:PMC9513992

[95] Akbay EA,Liu Y.Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade.J Thorac Oncol2017;12:1268-79

[96] Dutta R,Sharma HP.Mapping the immune landscape in small cell lung cancer by analysing expression of immuno-modulators in tissue biopsies and paired blood samples.Sci Rep2023;13:3739 PMCID:PMC9988882

[97] Wen J,Cheng Q,Liu F.A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.Sci Rep2021;11:22502 PMCID:PMC8602416

[98] Fourcade J,Benallaoua M.Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8⁺ T cell dysfunction in melanoma patients.J Exp Med2010;207:2175-86

[99] Li R,Zhang Z.Prognostic significance of lymphocyte-activation gene 3 (LAG3) in patients with solid tumors: a systematic review, meta-analysis and pan-cancer analysis.Cancer Cell Int2023;23:306 PMCID:PMC10693146

[100] Rudin CM,Soo RA.SKYSCRAPER-02: tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer.J Clin Oncol2024;42:324-35 PMCID:PMC10824371

[101] Subramanian M,Barisas D,Choi K.Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy.Cell Rep Med2023;4:100896 PMCID:PMC9873950

[102] Ren S,Liu H,Yu Z.Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.Thorac Cancer2024;15:1149-63

[103] Feig C,Kraman M.Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.Proc Natl Acad Sci U S A2013;110:20212-7

[104] Routy B,Derosa L.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science2018;359:91-7

[105] Lin Q,Sato N.Visualizing vasculature and its response to therapy in the tumor microenvironment.Theranostics2023;13:5223-46 PMCID:PMC10614675

[106] Lin CS,Lee MT,Tsao TC.Independent prognostic value of hypoxia-inducible factor 1-alpha expression in small cell lung cancer.Int J Med Sci2017;14:785-90 PMCID:PMC5562133

[107] Munksgaard Persson M,Monsef N.HIF-2α expression is suppressed in SCLC cells, which survive in moderate and severe hypoxia when HIF-1α is repressed.Am J Pathol2012;180:494-504

[108] Meder L,Thelen M.Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer.Cancer Res2018;78:4270-81

[109] Fan Y,Wang Q.Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): a multicenter, two-stage, phase 2 trial.J Thorac Oncol2021;16:299-309

[110] Stefanou D,Arkoumani E,Agnantis NJ.Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas.Histol Histopathol2004;19:37-42

[111] Han B,Nishio M.1789P second OS interim analysis from BEAT-SC: a randomized phase III study of bevacizumab (bev) or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).Annals of Oncology2024;35:S1063-4

[112] Ohe Y,Nishio M.BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).JCO2024;42:8001-8001

[113] Ma S,Liu Y.Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial.EClinicalMedicine2024;70:102543 PMCID:PMC10955204

[114] Shen G,Ren D.Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.J Hematol Oncol2018;11:120 PMCID:PMC6146601

[115] Wei Z,Li Y.Abstract A200: CBT-502 (TQB2450), a novel anti-PD-L1 antibody, demonstrates favorable activity in MC-38/H-11 murine colon and A375 human melanoma animal models.Molecular Cancer Therapeutics2018;17:A200-A200

[116] Zhong J,Liu Y.Association of antibiotic exposure with survival in patients with extensive-stage small cell lung cancer receiving immune checkpoint inhibitor therapy.Thorac Cancer2024;15:152-62

[117] Tong L,Shi X.Evaluating oral probiotic supplements as complementary treatment in advanced lung cancer patients receiving ICIs: a prospective real-world study.Cancer Control2024;31:10732748241253959 PMCID:PMC11089945

[118] Liu L,Wang X.Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment.Transl Oncol2023;33:101687 PMCID:PMC10206491

[119] Golden EB,Pellicciotta I,Helen Barcellos-Hoff M.Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death.Oncoimmunology2014;3:e28518 PMCID:PMC4106151

[120] Berghoff AS,Wilhelm D.Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).J Neurooncol2016;130:19-29

[121] Best SA,Souza-Fonseca-Guimaraes F.Harnessing natural killer immunity in metastatic SCLC.J Thorac Oncol2020;15:1507-21

[122] Chiang AC,Ashley K.Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.JCO2023;41:8597-8597

[123] George J,Abedpour N.Evolutionary trajectories of small cell lung cancer under therapy.Nature2024;627:880-9

[124] Lo YC,Vasmatzis G,Leventakos K.Subtype of SCLC is an intrinsic and persistent feature through systemic treatment.JTO Clin Res Rep2023;4:100561 PMCID:PMC10507151

[125] Yang F,Yang R.Integrative analysis of blood transcriptome profiles in small-cell lung cancer patients for identification of novel chemotherapy resistance-related biomarkers.Front Immunol2024;15:1338162 PMCID:PMC11217175

[126] Jin Y,Qin Z,Guo C.Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance.Acta Biochim Biophys Sin2023;55:948-55 PMCID:PMC10326415

[127] Shirasawa M,Shiraishi K.Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.Br J Cancer2023;129:2003-13 PMCID:PMC10703835

[128] Ji D,Zhang D.Somatic mutations and immune alternation in rectal cancer following neoadjuvant chemoradiotherapy.Cancer Immunol Res2018;6:1401-16

[129] Li L,Min Y.First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.BMC Cancer2023;23:318